The global morphine market is anticipated to showcase considerable growth during the forecast period. The increase in the number of product launches by the key market players is a key factor driving the growth of the global morphine drug market. Morphine is a kind of drug given to the patient in the form of capsules and tablets by mouth and injection through the skin. The opioid is a more effective treatment used in pain management to offer general and palliative care. Rising in legal approvals of opioids or opium for developing medicines in different under-developed nations by the government is one of the key opportunities for new and for existing players as well to expand their business across the globe.
A full report of Morphine Market is available at: https://www.omrglobal.com/industry-reports/morphine-market
In November 2018, the Food and Drug Administration (FDA) approved the R&D of morphine drug to develop new opioid painkiller. One of the novel product is Dsuvia is one of the morphine drug used by medical professionals under restricted regulations that are prescribed for emergency cases, in surgical operations by hospitals. Dsuvia dosage only prescribed when the patient is incapable to swallow the medicine. Sun Pharmaceutical Industries Ltd., Vertice Pharma LLC, Purdue Pharma LP, Rhodes Technologies LP, Teva Pharmaceutical, Mallinckrodt LLC, Allergan Plc, Hikma Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Egalet Corp., and so on are the key players operating in the global morphine market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/morphine-market-size
These players are actively engaged in making new product launches which in turn is driving the growth of the global morphine market. For instance, in August 2019, Upsher-Smith Laboratories, LLC had launched Morphine Sulfate Tablets, CII, 15, and 30 mg. According to the IQVIA, the morphine sulfate tablet market had US sales of approximately $49 million for the 12 months ending June 2019. In March 2019, Piramal Critical Care had launched Morphine Sulfate injection with Mitigo trademark in the US. The launched morphine sulfate injection is used for the treatment of intractable chronic pain. The injection has been launched in 10 mg/ml and 25 mg/ml concentrations. The company had launched this injection to diversify its presence in the field of anesthesia, pain management, and intrathecal therapy.
In January 2017, Lupin, Ltd. had launched its US FDA approval for morphine sulfate ER tablet (in strengthening 15 mg, 30 mg, 60 mg, 100 mg, and 200 mg). Morphine sulfate ER tablet is indicated for the management of pain severe enough to require daily, timely, long-term opioid treatment and for which the use of the alternative treatment options are inadequate.
Global Morphine Market Segmentation
By Type
- Capsules
- Oral Tablets
- Injection
By Application
- Cough Suppressant
- Diarrhea Suppressant
- Anesthesia
- Others
